Sampling circulating tumor cells for clinical benefits: how frequent? by unknown
JOURNAL OF HEMATOLOGY
& ONCOLOGY
Leong et al. Journal of Hematology & Oncology  (2015) 8:75 
DOI 10.1186/s13045-015-0174-9REVIEW Open AccessSampling circulating tumor cells for clinical
benefits: how frequent?
Sai Mun Leong1, Karen ML Tan1*, Hui Wen Chua1, Doreen Tan3, Delly Fareda3, Saabry Osmany4, Mo-Huang Li5,
Steven Tucker3 and Evelyn SC Koay1,2Abstract
Circulating tumor cells (CTCs) are cells shed from tumors or metastatic sites and are a potential biomarker for cancer
diagnosis, management, and prognostication. The majority of current studies use single or infrequent CTC sampling
points. This strategy assumes that changes in CTC number, as well as phenotypic and molecular characteristics, are
gradual with time. In reality, little is known today about the actual kinetics of CTC dissemination and phenotypic and
molecular changes in the blood of cancer patients. Herein, we show, using clinical case studies and hypothetical
simulation models, how sub-optimal CTC sampling may result in misleading observations with clinical consequences,
by missing out on significant CTC spikes that occur in between sampling times. Initial studies using highly frequent
CTC sampling are necessary to understand the dynamics of CTC dissemination and phenotypic and molecular
changes in the blood of cancer patients. Such an improved understanding will enable an optimal, study-specific
sampling frequency to be assigned to individual research studies and clinical trials and better inform practical
clinical decisions on cancer management strategies for patient benefits.
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Circulating tumor cells (CTCs), shed from primary or
metastatic tumor into the blood [1], may represent the
source of metastases and hence allow a “liquid biopsy”
for molecular characterization to further our under-
standing of the molecular mechanisms underlying me-
tastasis [2]. In the past decade, advances in technology
have allowed the development of assays for CTCs as
biomarkers for disease progression and therapeutic re-
sponse [3]. Numerous studies using different assays have
shown that CTCs may be used to predict disease pro-
gression and survival in metastatic and possibly even
early-stage cancer [4–16]. With the advent of precision
medicine, CTCs are currently being pursued as real-time
indicators for disease monitoring.
Currently, most studies on CTCs generally employ
single or infrequent CTC sampling points [4–16], with
the implicit assumption that changes in CTC number, as
well as phenotypic and molecular characteristics, are* Correspondence: karen_ml_tan@nuhs.edu.sg
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kinetics of these changes in the blood of cancer patients,
and the frequencies and time points chosen for their
sampling are usually arbitrary and not scientifically vali-
dated. Herein, we review examples from literature and
our own case studies to show how sub-optimal CTC
sampling may result in misleading observations with
clinical consequences. The measurement of CTCs is cur-
rently not yet recommended in cancer guidelines for
diagnosis or to influence treatment decisions [17]. In
exploring CTCs as biomarkers of disease progression
and therapeutic monitoring, the question of when and
how often to sample needs to be answered before CTCs
can be used to influence therapeutic decisions.
CTCs were first described in 1869 [1], but the clin-
ical relevance of CTCs was only demonstrated by
Cristofanilli et al. in 2004 in metastatic breast cancer pa-
tients [4]. In that study, a single measurement of >5 CTCs
before treatment was shown to be an independent pre-
dictor of progression-free survival (PFS) and overall sur-
vival (OS) in metastatic breast cancer [4]. More recently,
studies in patients with non-metastatic breast cancer also
demonstrated that the presence of ≥1 CTC predicted earlyticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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CTCs was also investigated for other cancer types such as
prostate, colorectal, lung, and ovarian cancers [6–9],
where CTC numbers at a single time point and exceeding
a defined cutoff value predicted for increased mortality.
Subsequent studies enumerating CTCs using different
assays, at multiple time points before, during, and after
treatment in breast, prostate, and colorectal cancers
showed that elevated CTC levels measured at any time
during the treatment course predicted for disease pro-
gression [12–15]. Conversely, reduction in CTCs post-
treatment was associated with improved PFS and OS
[14–16], suggesting that CTCs represent an indicator of
treatment failure and disease progression.
“Saw-toothed” response
Apart from enhancing prognostication, the use of mul-
tiple time points for sampling CTCs may reveal insights
into the nature of CTC dissemination in patients’ blood.
In 2008, using multiple time point measurements,
Pachmann et al. described three typical patterns of
changes in CTCs observed for non-metastatic breast
cancer patients undergoing adjuvant treatment: pattern
1—decrease in circulating epithelial tumor cells (CETC)
count (>10-fold), pattern 2—marginal changes in count
(<10-fold), and pattern 3—an increase or initial de-
crease with subsequent increase (“saw-toothed” pattern)
(>10-fold) [18]. Notably, the pattern of change in CETC
count during therapy was highly predictive of outcomes,
with a highly significant increased relapse-free survival
rate for patients with pattern 1 compared to pattern 2,
and for patients with pattern 2 compared to pattern 3
[18]. The stratification of patients by their patterns of
CTC changes by Pachmann et al. contrasts greatly with
most previous studies that used defined cut-off values
[4–9] and suggests that the pattern of CTC change itself
may be an important predictor for patient outcomes.
Similar saw-toothed patterns were reported in subse-
quent studies employing different CTC isolation strat-
egies, including the clinically validated FDA-approved
CellSearch assay [19–22]. Taken together, these data
appear to indicate that saw-toothed-like CTC count pat-
terns may be a common phenomenon occurring in can-
cer patients undergoing therapy. The mechanism behind
this phenomenon is currently unknown, but may be
related to differential drug sensitivities of the different
intra-tumoral regions that occur as a result of clonal het-
erogeneity within the primary tumor [23].
The saw-toothed count pattern suggests that CTC dis-
semination in the blood is not always continuous but
may occur in spurts during therapy. It thus follows that
depending on the time of CTC measurement, different
CTC counts will be obtained and in turn, different con-
clusions will be drawn with regard to the nature of thepatient’s real-time therapeutic response. This may ex-
plain why some studies, employing very few time points
of CTC measurement during therapy, appear not to sup-
port a correlation between CTC response and tumor
response. For example, Pierga et al. [24] examined the
changes in CTC count before and after neoadjuvant
therapy for stages II and III breast cancer patients and
showed that changes in CTC count did not correlate to
complete pathologic response, although CTC detection
was proven to be an independent prognostic factor
for early relapse [24]. Similar results were reported
by Riethdorf et al. [25] for the GeparQuattro trial,
which likewise employed a single measurement each for
pre- and post-neoadjuvant therapy [25]. In the landmark
study by Cristofanilli et al., only 50 % of patients with
progressive disease had increased CTC counts [4]. It can-
not be ruled out that transient rises in CTC counts oc-
curred in the other 50 % of the patients, but were missed
as only a single time point was used in the study. Uncer-
tainty regarding the timing of CTC measurements might
thus limit the predictive capacity of single or few time
point CTC measurements.
The issue of optimal sampling frequency
Given that different CTC count patterns may predict for
significantly varied relapse-free survival [18], it will be
important to distinguish between patients with invari-
able, gradual, or rapid decline, gradual or rapid increase,
or saw-toothed patterns of CTC response. As shown in
Fig. 1a, these different patterns cannot be distinguished
by infrequent counts. The effect of sub-optimal count
frequency on the patient’s CTC response pattern is fur-
ther illustrated by the following case studies:
(i) Using a typical saw-toothed response curve of a breast
cancer patient from response group 3, as presented by
Pachmann et al. [18], we simulated the count patterns
observed when the frequency of blood sampling is
halved. Depending on the sampling dates chosen,
the patient could have a pattern resembling that of
response group 1 (decrease in cell numbers), response
group 2 (consistent cell numbers), or response group 3
(increase in cell numbers) when the number of sampling
points is decreased from six to three points (Fig. 1b).
(ii) A recent case report of a metastatic breast cancer
patient by Marsland and Schuur [19] demonstrated a
saw-toothed pattern of CTC counts during the patient’s
course of therapy (Fig. 2a). CTCs were sampled
three-monthly in 2007 and monthly in 2008. Using
the CellSearch assay, a spike of CTCs from 0 to 8
was observed in May 2008, which corresponded with
disease progression (Fig. 2a). We simulated the count
patterns observed when the frequency of blood sampling
is halved, using alternate time points. Depending on the
Fig. 1 CTC response patterns in cancer patients undergoing therapy. a Hypothetical CTC count patterns corresponding to patient response to
therapy. The light green circles represent frequent sampling times, and the dark green circles represent infrequent sampling times. b CTC count
pattern of a breast cancer patient from response group 3 of Pachmann et al. [18]. CTC count patterns are simulated when the frequency of
sampling is halved from six to three sampling points. The sampling points chosen for each simulation are numbered
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no CTCs during disease progression in 2008 (Fig. 2a).
(iii) We monitored our own prostate cancer patient
using the CellSearch assay. A spike in CTCs from 1 to
5 was observed within 1 month, which correlated
with prostate-specific antigen (PSA) levels and disease
progression by PET/CT imaging (Fig. 2b). We simulated
the count patterns observed when the frequency of blood
sampling is halved, using alternate time points. The two
different count patterns produced show that the spike
in CTCs could be missed if CTC sampling were less
frequent (Fig. 2b).
(iv) Another case is our own patient with metastatic
prostate cancer, who had weekly CTC sampling at
each chemotherapy session. CTCs were isolated using
a previously published size-exclusion method [26].
Using this method, which is not dependent on epithelial
markers, mesenchymal CTCs that have been associated
with therapeutic resistance and disease progression [21]
can be captured together with the epithelial ones. For this
patient, transient saw-toothed-like spikes in CTC count,
with a duration span of not more than 1 month,
were observed, and these transient increases preceded
progression of osseous disease as shown by a PET bonescan (Fig. 2c). We performed a simulation test to
determine the CTC count pattern generated when
the sampling frequency was hypothetically decreased
from weekly to monthly. Different start dates and
intervals of 4–7 weeks between CTC measurements
were simulated. Interestingly, 57.2 % (8 out of 14) of the
simulated models generated failed to recapitulate the
saw-toothed pattern of response group 3. In fact, these
simulated count patterns (“Simulation 1”, Fig. 2c)
resemble more closely the invariable pattern of response
group 2 in Pachmann et al.’s study [18].
All four case studies, using different CTC isolation
technologies including the FDA-approved CellSearch
assay, demonstrate how patients using a sub-optimal
count frequency may end up with different count pat-
terns indicative of different therapeutic responses and
varied predictions of relapse-free survival. Depending on
the start date and sampling points chosen, there is a
good chance that the physician may be misled into con-
cluding that the patient is responding to treatment,
when the latter may in fact be developing resistance to
therapy. Published studies typically measured CTCs at
monthly intervals during therapy to assess the patients’
Fig. 2 Case studies of CTC count patterns in cancer patients. a CTC count pattern of a metastatic breast cancer patient from Marsland and Schuur [19].
CTC count patterns are simulated when the frequency of sampling is halved. Alternate time points were used for each simulation. PD indicates
progressive disease and PR indicates partial response. b Longitudinal monitoring of CTC count and PSA level in a prostate cancer patient. CTCs
were measured using the CellSearch assay. CTC count patterns are simulated when the frequency of sampling is halved. Alternate time points
were used for each simulation. PD indicates progressive disease. c Longitudinal monitoring of CTC count and PSA level in a metastatic prostate
cancer patient. CTCs were imaged at ×20 magnification and identified as Hoechst (blue) positive and CD45 (green) negative, and white blood cells
(WBCs) as both Hoechst and CD45 positive. Some CTCs were also EpCAM/cytokeratin (red) positive, while WBCs were EpCAM/cytokeratin negative.
The foremost graph shows concentration of PSA with time. The second graph behind shows the CTC count over time. The third to fifth graphs
behind are representatives of simulated models for monthly CTC counting. The green circles represent sampling times. The proportion of
simulations represented by each model is indicated as percentage. A [18F]NaF-PET bone scan in July 2012 vs. April 2012 showed progression
of osseous disease including new lesions (as indicated by blue arrows)
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derstanding of the kinetics of CTC dissemination and
turnover in blood in response to treatment, it is un-
known if a monthly frequency offers sufficient analytical
resolution in deciphering the patient’s therapeutic re-
sponse pattern based on changes in CTC number.
CTC enumeration is only the tip of the iceberg
The above case studies demonstrate the possibility of
misleading interpretation of disease progression andtreatment responses based on CTC numbers, given in-
sufficient sampling. This assumption is made purely
based on CTC total numbers. Apart from the choice of
sampling frequency, other factors may further confound
attempts to decipher the patients’ actual therapeutic re-
sponses based on CTC number. One such factor is the
technology used in isolating CTCs from patients’ periph-
eral blood samples. Currently, the understanding of
CTCs is very much dependent on the technological ap-
proaches used for their detection and isolation. Many
Leong et al. Journal of Hematology & Oncology  (2015) 8:75 Page 5 of 8different CTC detection technologies have been devel-
oped, including nucleic acid-based detection [27, 28], de-
tection based on physical properties such as larger size
of epithelial cells [29], differences in density [30], charge
[31], migratory properties [32, 33], and properties of spe-
cific cell types [34, 35]. Approaches of isolation of CTCs
by virtue of their increased size using filtration are lim-
ited by the variability in heterogeneous CTC sizes. The
most widely used CTC isolation approach relies on
antibody-based capture of CTCs which express epithelial
cell surface markers such as the epithelial cell adhesion
molecule (EpCAM) that are absent from normal leuko-
cytes [4, 32, 33]. The FDA-approved CellSearch system
(Veridex) which uses this approach is the most standard-
ized platform but suffers from low sensitivity [36]. This
approach is also limited by the failure to detect CTCs
that have undergone epithelial-mesenchymal transition
(EMT), a key process involved in metastasis [37].
Given the lack of a gold standard to compare CTC iso-
lation technologies to, it remains a question whether
current methods are detecting all CTCs reliably [38].
Even though technological advances have improved
CTC isolation efficiency, due to the universal issue of
leukocyte contamination, identification of all CTCs with
heterogeneous expression markers can be challenging.
Furthermore, not all CTCs detected may be clinically
relevant [38]. Patients with benign inflammatory condi-
tions may have viable circulating epithelial cells detected
by current CTC assays [39]. Because some CTCs may be
undetected and some detected CTCs may not be clinic-
ally relevant, CTC enumeration by itself may not be a
good marker for disease progression. An ambiguous
choice of sampling time points only serves to further
undermine the utility of CTC counting for clinical use.
To this end, further characterization of the detected
CTCs by size, the presence of clusters [40], or other
phenotypic or molecular properties may add information
for reliable prediction of treatment responses.
Sampling for molecular characterization
CTCs may be shed from different sites within the tumor,
which are heterogeneous, or from metastases. Molecular
characterization of the CTCs such as expression profil-
ing to detect organ-specific metastatic signatures may
aid diagnostic and therapeutic strategies [38]. Molecular
analysis of CTCs may provide a “real time” noninvasive
approach for tumor cell genotyping, which can be re-
peated during the course of therapy to monitor the ac-
quisition of novel genetic abnormalities in response to
drug exposure. Moreover, different CTC parameters can
influence how CTCs reflect disease progression. The
proportion of cells in proliferative or apoptotic status
varies during treatment and across patients [41]. The
androgen receptor (AR) subcellular localization variesduring treatment of androgen deprivation therapy [42].
A simple enumeration of CTCs without molecular
and/or phenotypic characterization may lead to wrongful
clinical assumptions and consequences. Like CTC enu-
meration, appropriate choice of sampling frequency for
molecular and/or phenotypic characterization may be
necessary for accurate interpretation of the patients’ re-
sponses to therapies. In view of this, we describe below
two hypothetical examples of how insufficient sampling
may demonstrate the possibility of misleading interpret-
ation of disease progression and treatment responses
based on molecular characterization of CTCs.
Advanced CTC analysis, such as genomic profiling,
will likely increase the clinical value of CTCs as bio-
markers and therapeutic targets. The use of targeted
therapies has achieved considerable success; however,
many patients relapse due to drug resistance [43]. The
detection of small numbers of resistant CTCs could
prompt the clinician to use alternative treatment strat-
egies that might prevent resistant clones from expanding
to dominate the tumor cell population [43]. Using serial
CTC samples from lung cancer patients, Maheswaran
et al. demonstrated evolution of T790M and other epi-
dermal growth factor receptor (EGFR)-activating muta-
tions during treatment with the tyrosine kinase inhibitor,
Gefitinib [20]. The T790M missense mutation occurs
within the EGFR kinase domain and prevents binding of
Gefitinib to this region while preserving catalytic activity
[44]. In their study, the sampling interval used varied
from 30 to 100 days, which corresponds to 2–7 bi-
weekly cycles of chemotherapy [20]. To save the patient
a few cycles of ineffective therapy, we propose increasing
the frequency of CTC sampling, which may permit earl-
ier detection of T790M emergence. This, in turn, will
enable earlier initiation of subsequent chemotherapy to
eradicate the resistant clones, which may improve sur-
vival outcome [45, 46]. In a hypothetical situation as
depicted in Fig. 3a, the choice of a bi-weekly monitoring
interval over a bi-monthly one saves the patient about 6
weeks of ineffective treatment with the targeted therapy,
due to earlier detection of the mutation conferring re-
sistance with more frequent sampling. Subsequent ther-
apy can then be initiated earlier, and earlier time to
chemotherapy initiation of 4–8 weeks has been shown
to confer significant overall survival benefit in patients
with colorectal and breast cancers [47–49].
Besides mutation analysis, other molecular assays of
CTCs have also been investigated as indicators of treat-
ment response. Using an RNA in situ hybridization assay
on CTCs isolated from an index breast cancer patient,
Yu et al. demonstrated association of disease progression
and treatment failure with EMT [21]. In this study,
CTCs were assayed at 1–3-monthly intervals, with the
mesenchymal phenotype correlating positively with CTC
Fig. 3 Hypothetical models of different sampling times for molecular assays of CTCs. a CTC count pattern and resistance mutation (Mut X)
detection in a hypothetical cancer patient on targeted therapy. Mut X indicates presence of the mutation at low allele frequency. CTC count
patterns and resistance mutation detection are simulated when the frequency of sampling is increased from once in 2 months (red squares) to
once in two weeks (green circles). The bars below show the impact of earlier resistance mutation detection on choice of therapy. The red bars
indicate the therapeutic strategy with infrequent CTC sampling while green bars indicate the therapeutic strategy with frequent CTC sampling.
Time saved will vary, depending on when Mut X is detected at high allele frequency between week 6 and 15. b CTC count pattern and
epithelial-mesenchymal phenotypes in a hypothetical patient with CTCs oscillating between the epithelial and mesenchymal phenotypes.
Frequent sampling time is indicated in red, while infrequent sampling times are simulated in blue (infrequent sampling 1) and green (infrequent
sampling 2). Infrequent sampling 1 and 2 differ in their start time for first sampling. The proportion of mesenchymal phenotype is indicated in the
bars below in blue while that of epithelial phenotype is indicated in white
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EMT in relation to metastasis and chemotherapeutic
treatment is not well understood. As shown in a
hypothetical situation (Fig. 3b), for a patient with CTCs
oscillating between epithelial and mesenchymal pheno-
type with time, inadequate sampling may give rise to a
misleading trend, e.g., an apparent mesenchymal-to-
epithelial phenotypic change of “infrequent sampling 1”
can give a false impression of therapeutic responsive-
ness, while a perpetual epithelial phenotype with low
CTC count of “infrequent sampling 2” can mislead phy-
sicians into thinking that the disease is under remission.
Perspective
The case studies presented above highlight the import-
ance of understanding the precise kinetics of CTC dis-
semination before optimal count frequency can be
assigned for large-scale trials and future clinical practice.
As shown in the two hypothetical examples above, with-
out appropriate frequency of CTC sampling, molecular
analysis of CTCs may lead to potentially wrong assump-
tions or delayed diagnosis with clinical consequences.
To this end, we propose that initial systematic studies
involving highly frequent (e.g., weekly) sampling tounderstand the kinetics of CTC dissemination in patients
of different cancer types, stages of disease, and treatments.
A high-resolution “count-scape” will permit visualization
of the actual CTC response patterns manifested in differ-
ent scenarios. In the case of patients with saw-toothed re-
sponses, measurement of the range of duration spans of
the CTC spikes may then lead to better understanding of
the kinetics of CTC spurts and enable determination of
the optimal sampling intervals to employ. This systematic
approach is perceivably superior to the arbitrary manner
in which sampling frequencies are currently being selected
and will likely lead to a better gauge of the actual thera-
peutic responses based on changes in CTC count. While
the high cost and resource requirements associated with
highly frequent CTC sampling may be prohibitive, these
may be overcome in the near future by technological
advances leading to low-cost and high-throughput CTC
isolation devices. Before CTC-based molecular markers
can be translated to the real-world clinical setting, system-
atic studies with high-frequency sampling of CTCs will
likely be required to establish the dynamics of the pheno-
typic and genetic changes occurring in CTCs.
CTCs capture real-time information about the biology
of the cancer; changes in CTCs can thus reveal changes
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of CTCs is its incorporation into disease management
strategies. CTCs may be used, in conjunction with radio-
logic imaging, serum tumor markers, and clinical assess-
ment, for real-time monitoring of disease status and
therapeutic efficacy. At the moment, the sampling fre-
quency represents a major conundrum and an unre-
solved unknown in the study and clinical application of
CTCs. Current studies in CTC are probably limited in
sampling frequency more as a result of cost and resource
implications than scientific rationale. To fulfill the full
clinical potential of CTCs, an initial study involving
high-frequency blood sampling appears to be the un-
avoidable trip that all CTC researchers must take to
ensure there is no loss of crucial information during
time-course investigations.
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